News Overview

Devicam Capital LLP has submitted to the Exchange a copy of Disclosure under Regulation 10(5)-Intimation to stock Exchanges in respect of acquisition under Regulation 10(1) (a) of SEBI ( SAST) Regulations, 2011

Tanla Platforms Limited has informed the Exchange about Closure of trading window

Faze Three Limited has informed the Exchange that at Dun & Bradstreet Business Enterprises of Tomorrow 2022 Business Excellence Awards, the event held on the eve of November 29, 2022, Dun & Bradstreets has released its publications - Leading SMEs of India 2022 and Leading Mid-Corporates of India 2022 and Interview of Mr. Ajay Anand - Managing Director of the Company has been published in Dun & Bradstreet publication - Leading Mid-Corporates of India 2022. We are enclosing herewith the relevant Interview page from the said publication.

IRIS Business Services Limited has informed the Exchange about press release dated 30-Nov-2022 titled ???IRIS CARBON?? Office 365 Based Disclosure Management Module

This has reference to the Board Meeting outcome filed on 04th November, 2022 intimating the declaration of 2nd Interim dividend of Rs. 8.50 per share. The record date for the same was fixed as 17th November 2022. We would like to inform that the payment of the dividend has been completed by credit to the eligible shareholders on 28th November 2022.

On 2 December 2022

On 3 December 2022

Biocon Biologics, subsidiary of Biocon announced today that it has successfully completed its multi-billion-dollar (USD) acquisition of the global biosimilars business of its partner Viatris Inc. (NASDAQ: VTRS). Biocon Biologics and Viatris have obtained all applicable approvals from key global regulators including the U.S. Federal Trade Commission, the Competition Commission of India and the Reserve Bank of India, and its investors. Effective from the date […]

Union Bank of India has allotted Unsecured, Subordinated, Non-Convertible, Taxable, Fully Paid-Up Basel III Compliant Tier- 2 Bonds in the nature of Debentures eligible for inclusion in Tier 2 Capital (Bonds) in two tranches of Rs.1500 crore (ISIN: INE692A08219,Series XXXVI-A) and Rs.700 crore (ISIN: INE692A08201,Series XXXVI-B) aggregating to Rs.2200 crore on 29 November 2022.Powered by Capital Market – Live News

Gland Pharma announced that it has through its wholly owned subsidiary Gland Pharma International, Singapore entered into a Put Option Agreement to acquire 100% of Cenexi Group for an Equity Value not exceeding Euro 120 Mn (Enterprise Value of Euro 230 Mn). Founded in 2004, Cenexi, along with its Subsidiaries, is engaged primarily in the business of Contract Development & Manufacturing Organisation (CDMO) of pharmaceutical […]